2020 Annual Meeting | C247 - Autoimmune Neurology 2 Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

Date Thursday 04/30/20

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eoin P. Flanagan, MBBCh, FAAN

Topic(s) Autoimmune Neurology

Learning Objectives Participants should be able to understand the autoantibody nomenclature, recognize autoimmune neurologic disorders occurring in novel settings, know the neurologic and cancer associations of the autoantibodies, know the pitfalls in antibody testing, know the appropriate oncological evaluations for paraneoplastic neurologic disorders, understand how to treat autoimmune encephalitis and what the prognosis is and how to predict prognosis.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Program Tracks Neurohospitalist

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic, Audience Participation

Event Timeline
03:30 PM - 04:10 PM	Speaker	Diagnostic Approach to Autoimmune Encephalitis Eoin P. Flanagan, MBBCh, FAAN
04:10 PM - 04:45 PM	Speaker	Neurologic Complications of Immune Checkpoint Inhibitors Anastasia Zekeridou, MD, PhD, FAAN
04:45 PM - 05:20 PM	Speaker	Autoimmune Encephalitis: Treatment, Prognosis, and Predictive Scores Maarten J. Titulaer, MD, PhD
05:20 PM - 05:30 PM	Q&A	Questions and Answers
05:30 PM - 06:00 PM	Discussion	Continuing the Conversation

Faculty Disclosures
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Maarten J. Titulaer, MD, PhD	The institution of Dr. Titulaer has received research support from Dutch Epilepsy Foundations (NEF 19-08). The institution of Dr. Titulaer has received research support from CSL Behring. The institution of Dr. Titulaer has received research support from UCB. The institution of Dr. Titulaer has received research support from Netherlands Organisation for Scientific Research (ZonMW, Memorabel initiative and E-RARE UltraAIE) . The institution of Dr. Titulaer has received research support from Horizon Therapeutics / Amgen. The institution of Dr. Titulaer has received research support from Dioraphte (charity). The institution of Dr. Titulaer has received research support from Guidepoint Global LLC. The institution of Dr. Titulaer has received research support from ArgenX. Dr. Titulaer has received publishing royalties from a publication relating to health care.
Anastasia Zekeridou, MD, PhD, FAAN	The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��